The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
After an initial dip, BioInvent International saw its shares close up 1.2% at 17.22 kronor today, when the Swedish biotech revealed that a licensing partner was pulling out of their agreement. 12 January 2024
Industry analyst GlobalData has presented research into the growing market for GLP-1 therapies, noting the significance of Roche’s recent acquisition in this area. 12 January 2024
A generics drugmaker has had its Abbreviated New Drug Application for the radiopharmaceutical 177Lu-PNT2003 accepted by the US Food and Drug Administration. 12 January 2024
Swiss specialty pharma Santhera Pharmaceuticals has announced that Agamree (vamorolone) has been approved in the UK for Duchenne muscular dystrophy (DMD) in patients four years of age and older, independent of the underlying mutation and ambulatory status. 12 January 2024
As generic competition has eroded sales of Fampyra (fampridine), US biotech major Biogen has decided to return its ex-USA rights to the multiple sclerosis treatment to licensor Acorda Therapeutics . 12 January 2024
US biopharma Emergent BioSolutions has secured a procurement contract with a maximum value up to $235.8 million to supply BioThrax (Anthrax Vaccine Adsorbed) for use by all branches of the US military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. 12 January 2024
Shares of USA-based was Xeris Biopharma (were up 12% to $2.67 in morning trading yesterday, after it announced a licensing deal with biotech major Amgen. 12 January 2024
The US Food and Drug Administration (FDA) has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. 12 January 2024
China-based contract research, development and manufacturing organization (CRDMO) WuXi Biologics saw its shares jump nearly 9% to HK$30.45 by close of trading today, after it announced a new collaboration. 11 January 2024
The New Drug Application (NDA) for China-based Hutchmed’s sovleplenib as a treatment of adult patients with primary immune thrombocytopenia (ITP) has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). 11 January 2024
Privately-held Spanish drugmaker Ferrer has reported that the Phase III ADORE trial of oral edaravone formulation (FAB122) in amyotrophic lateral sclerosis (ALS) did not meet primary or key secondary endpoints. 11 January 2024
Grifols, the Spanish producer of blood plasma-based products, is not taking the stock market damage done to the company by UK short seller Gotham City Research without a fight. 11 January 2024
China’s Shanghai Henlius Biotech today announced a strategic collaboration with USA-based Sermonix Pharmaceuticals for exclusive rights to develop, manufacture and commercialize Sermonix’ lead investigational drug, lasofoxifene, in China. 11 January 2024
A major equity investment will see Germany’s Bayer and New York-based life science investor RTW Investments take a stake in a Chinese biotech working on heart and eye conditions. 11 January 2024
The European Commission (EC) has granted conditional marketing authorization for Krazati (adagrasib), from US biotech Mirati Therapeutics. 11 January 2024
Coherus Biosciences has notified the US markets authority that it will terminate a collaboration with Shanghai-based Junshi Biosciences related to an anti-TIGIT candidate. 11 January 2024
Japanese drugmaker Eisai announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of its Alzheimer’s disease drug Leqembi (lecanemab) which is currently under review by the European Medicines Agency (EMA). 11 January 2024
Swiss-American eye specialist Alcon has announced positive topline results from two Phase III trials evaluating the efficacy and safety of AR-15512. 11 January 2024
Danish diabetes care giant Novo Nordisk has release top-line results from the COMBINE 3 Phase IIIa trial of once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide. 11 January 2024